HB Wealth Management LLC Acquires 3,460 Shares of Johnson & Johnson (NYSE:JNJ)

HB Wealth Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 207,479 shares of the company’s stock after buying an additional 3,460 shares during the quarter. HB Wealth Management LLC’s holdings in Johnson & Johnson were worth $30,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Financial & Tax Architects LLC lifted its stake in shares of Johnson & Johnson by 6.0% in the fourth quarter. Financial & Tax Architects LLC now owns 41,533 shares of the company’s stock valued at $6,006,000 after buying an additional 2,347 shares during the period. Gill Capital Partners LLC lifted its position in shares of Johnson & Johnson by 14.8% in the 4th quarter. Gill Capital Partners LLC now owns 2,168 shares of the company’s stock worth $314,000 after acquiring an additional 279 shares during the period. CGN Advisors LLC grew its holdings in shares of Johnson & Johnson by 8.7% during the 4th quarter. CGN Advisors LLC now owns 27,217 shares of the company’s stock worth $3,936,000 after purchasing an additional 2,169 shares in the last quarter. Premier Path Wealth Partners LLC increased its position in shares of Johnson & Johnson by 34.4% during the fourth quarter. Premier Path Wealth Partners LLC now owns 16,074 shares of the company’s stock valued at $2,325,000 after purchasing an additional 4,111 shares during the period. Finally, Howard Financial Services LTD. raised its stake in shares of Johnson & Johnson by 34.3% in the fourth quarter. Howard Financial Services LTD. now owns 4,950 shares of the company’s stock valued at $716,000 after purchasing an additional 1,265 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $147.03 on Monday. The stock has a 50-day simple moving average of $148.51 and a 200 day simple moving average of $156.03. The stock has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.29.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.